ArticleCancer immunology, immunotherapy : CII2023

Pembrolizumab near the end of life in patients with metastatic pancreatic cancer: a multi-site consecutive series to examine survival and patient treatment burden.

Michael H Storandt et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.